Skip to main content
OpenTrials
Completed

NCT Number: NCT07038577

Impact of Fenugreek Supplementation on Obesity and Hyperglycemia Among Diabetic Adults in Saudi Arabia

The goal of this clinical trial is to learn if Fenugreek seed powder helps lower body weight and blood sugar in adults with type 2 diabetes who are overweight or obese. The main questions it aims to answer are:

Does Fenugreek lower body mass index (BMI)? Does Fenugreek lower fasting blood sugar, random blood sugar, and HbA1c levels? Researchers will compare people who take Fenugreek along with their regular diabetes care to people who receive only standard diabetes care, to see if the Fenugreek supplement adds extra benefits.

Participants will:

Take 10 grams of Fenugreek seed powder twice a day (before breakfast and dinner) for 3 months.

Follow their usual diabetes treatment and a recommended meal plan. Visit the clinic four times during the study to check weight and blood sugar levels.

This study is being done in Hail City, Saudi Arabia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus (T2DM) Body Weight Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Hyperglycemia Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity and Type 2 Diabetes Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Hail

Ha'il, 55424, Saudi Arabia

About this study

This clinical trial tested whether Fenugreek seed powder, a natural dietary supplement, could help lower blood sugar and reduce body weight in adults with type 2 diabetes. The study was conducted in Hail City, Saudi Arabia, and involved 80 participants who were either overweight or obese and diagnosed with type 2 diabetes.

Participants were assigned to one of two groups:

The intervention group received 10 grams of Fenugreek seed powder twice daily (before breakfast and dinner) for three months, in addition to their usual diabetes treatment and a standard meal plan.

The control group received only their standard diabetes care and meal plan, without the Fenugreek supplement.

The study used a quasi-experimental pretest-posttest design. Participants' weight (BMI), fasting blood sugar (FBS), random blood sugar (RBS), and HbA1c were measured at the start and monitored throughout the three-month period. Data were collected from local clinics and hospitals that serve people with diabetes in the region.

This study aims to provide evidence on the potential role of Fenugreek as a safe, culturally accepted, and cost-effective supplement that can support diabetes management and reduce obesity-related complications in the Saudi population

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 18 years or older

Diagnosed with type 2 diabetes mellitus

Body Mass Index (BMI) classified as overweight or obese

Receiving standard diabetes treatment (e.g., oral hypoglycemic agents)

Able and willing to provide informed consent

Residing in Hail City, Saudi Arabia

Exclusion criteria

Diagnosed with type 1 diabetes mellitus

Currently using insulin therapy

Pregnant or breastfeeding women

Known allergy or sensitivity to Fenugreek

Diagnosed gastrointestinal diseases or malabsorption conditions

Participation in another clinical trial within the past 3 months

Any serious medical or psychiatric condition that, in the opinion of the investigators, could interfere with study participation

-

Treatment and study plan

Fenugreek Seed Powder

Other

Participants in the intervention group received 10 grams of ground Fenugreek seed powder, administered twice daily (before breakfast and dinner), for a total of 3 months. The Fenugreek powder was consumed mixed with water, in addition to the participants' regular antidiabetic medications and a standardized meal plan. The supplement was provided in a non-encapsulated, natural powdered form, and was not combined with any other herbal or pharmaceutical products.

Primary outcomes

  1. Change in Body Mass Index (BMI)

    Time frame: Baseline and 3 months after intervention

    BMI will be calculated as weight in kilograms divided by the square of height in meters (kg/m²).

Secondary outcomes

  1. Change in Fasting Blood Sugar (FBS)

    Time frame: Baseline and 3 months after intervention

    Fasting blood sugar will be measured in mg/dL to assess glycemic control

  2. Change in Random Blood Sugar (RBS)

    Time frame: Baseline and 3 months after intervention

    Random blood sugar will be measured in mg/dL to evaluate fluctuations in blood glucose levels.

  3. Change in Hemoglobin A1c (HbA1c)

    Time frame: Baseline and 3 months after intervention

    HbA1c will be measured as a percentage to assess long-term glycemic control.

Sponsors and collaborators

Lead sponsor

University of Hail

Other

Registry information

Official study title

Impact of Fenugreek Supplementation on Obesity and Hyperglycemia Among Diabetic Adults in Saudi Arabia: A Quasi-Experimental Study

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 26, 2025
Registry last updated
Jun 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.